Schering misjudges Claritin inventory
Schering-Plough is reducing its fourth quarter earnings estimate by about $250 mil. (16-18 cents per share) because of "a more-rapid-than-anticipated decline in U.S. prescriptions for Claritin" following the OTC launch in December. Schering says it will not record any sales on shipments of Rx product to wholesalers until an actual prescription is dispensed...
You may also be interested in...
Schering-Plough's poor first quarter results reflect inventory buildup issues beyond Rx Claritin
Data presented at AAAI meeting show reduced annualized asthma exacerbation rates across all patient populations, but doctors are unlikely to switch patients served well by existing biologics.
The RNA drug’s accelerated approval brings Sarepta’s exon-skipping market share to nearly 30%.